Who are ExoFlo's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Topical lyophilized exosomes application, CardiolRx.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/exoflo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ExoFlo — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ExoFlo (ExoFlo) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Exosome therapy. Area: Regenerative Medicine / Orthopedics.

phase 3 Exosome therapy Regenerative Medicine / Orthopedics Biologic Live · refreshed every 30 min

Target snapshot

ExoFlo (ExoFlo) — Direct Biologics, LLC. ExoFlo is an exosome-based therapeutic that delivers regenerative factors to promote tissue repair and reduce inflammation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
ExoFlo TARGET	ExoFlo	Direct Biologics, LLC	phase 3	Exosome therapy
Topical lyophilized exosomes application	Topical lyophilized exosomes application	Instituto de Oftalmología Fundación Conde de Valenciana	marketed	Exosome therapy
CardiolRx	CardiolRx	Cardiol Therapeutics Inc.	phase 3	Exosome therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Exosome therapy class)

Cardiol Therapeutics Inc. · 1 drug in this class
Direct Biologics, LLC · 1 drug in this class
Instituto de Oftalmología Fundación Conde de Valenciana · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ExoFlo — Competitive Intelligence Brief. https://druglandscape.com/ci/exoflo. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing